TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02749552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
Study: NCT05129657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine
Study: NCT05608694

Intervention type: OTHER
Group type: OTHER
Intervention: Prostate MRI
Description: Group placement is determined by GRS score, Family history, and germline testing

Intervention type: OTHER
Group type: OTHER
Intervention: Prostate MRI
Description: Group placement is determined by GRS score, Family history, and germline testing

Intervention type: OTHER
Group type: OTHER
Intervention: Prostate MRI
Description: Group placement is determined by GRS score, Family history, and germline testing

Intervention type: OTHER
Group type: OTHER
Intervention: Prostate MRI
Description: Group placement is determined by GRS score, Family history, and germline testing
Study: NCT05580107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDPK67b
Description: 24 mg or 48 mg
Study: NCT06045936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 2 teaspoons of 2% lidocaine injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection
Study: NCT05181215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monomethyl Fumarate 190 Mg
Description: 2 x oral 95 mg capsules, delayed-release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diroximel Fumarate 462 mg
Description: 2 x 231 mg capsules, delayed-release
Study: NCT05459675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low-calorie diet
Description: Meal replacement (800 kcal/day, protein 90 g/day)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Bariatric surgery will be performed by single surgeon at Ramathibodi Hospital Mahidol University, Thailand. Postoperative diet progression according to the current guideline will be prescribed from early post-op period to 1 year after surgery
Study: NCT05955729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-duty Nap
Description: For 12 weeks, an opportunity for a 30-minute nap during the night shift, between 1 a.m. and 4 a.m., in a quiet room with facilities for lying down.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition (30-min rest)
Description: For 12 weeks, an opportunity for a 30-minute rest during the night shift, between 1 a.m. and 4 a.m., in a quiet room without facilities for lying down or napping.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoPAT
Description: The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoPAT
Description: The EndoPAT device® measures vascular reactivity after a 5-minute occlusion on one arm.~This device measures changes in vascular tone induced by the endothelium at fingertip level using a pair of plethysmographic sensors. The measurement consists of performing a reference recording for 5 minutes on the 2 arms, then a test arm is chosen to perform an occlusion for 5 minutes while continuing the recording.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Popmeter®
Description: The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Popmeter®
Description: The tool is connected to the caregiver's finger and toe via photodiode sensors. Its simple operation enables reproducible measurement of the propagation speed of the pulse wave in 14 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Panasonic EW3109
Description: Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.
Study: NCT04935177

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PLEX
Description: PLEX is performed according to the respective site's standard procedure for desensitization.

Intervention type: DRUG
Group type: OTHER
Intervention: IVIg
Description: IVIg prepared from a pool of immunoglobulins from the plasma of thousands of healthy donors is administered in accordance with respective site's standard procedure for desensitization.
Study: NCT05955729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Panasonic EW3109
Description: Diastolic and systolic blood pressure measured 3 times in succession using an automatic blood pressure monitor (Panasonic EW3109) in the sitting position on the left arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECG Holter
Description: The Holter takes an ECG during the subject's daily activities at home.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG Holter
Description: The Holter takes an ECG during the subject's daily activities at home.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting blood sample
Description: 15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fasting blood sample
Description: 15 ml blood sample (venous sampling) will be taken to measure inflammatory biomarkers (hsCRP, IL-6 TNF-α, IL-1β) and blood markers of endothelial function (NO, CRP, SOD, IL-18).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pichot fatigue scale
Description: The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pichot fatigue scale
Description: The Pichot fatigue scale is an 8-item questionnaire, with a score above 22 indicating excessive fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: French version of the Recovery Needs Scale (BRD)
Description: BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: French version of the Recovery Needs Scale (BRD)
Description: BRD questionnaire consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Short-Form 36 (SF-36)
Description: The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Short-Form 36 (SF-36)
Description: The SF-36 questionnaire is used to assess quality of life. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).
Study: NCT04935177

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-CD20 antibodies
Description: Rituximab and other anti-CD20 according to the respective site's standard procedure for desensitization.

Intervention type: DRUG
Group type: OTHER
Intervention: Eculizumab
Description: Eculizumab according to the respective site's standard procedure for desensitization.
Study: NCT06446050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-L
Description: Human umbilical cord-derived mesenchymal stem cells (MSCs) genetically modified to express antitumor chemokine and co-stimulatory molecule will be administered intravenously at a dose of 1/2/3 x 10\^6 cells/kg, every 21 days for at least 6 cycles of treatment.
Study: NCT05129657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1012914, A nicotine pouch product with 4 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1012915, A nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1012915, A nicotine pouch product with 8 mg of nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1012915, A nicotine pouch product with 8 mg of nicotine
Study: NCT04785144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.351
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
Study: NCT05955729

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: 24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality
Study: NCT04628793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined
Study: NCT06421506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Less invasive surfactant administration during high flow nasal cannula treatment
Description: Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.
Study: NCT04935177

Intervention type: OTHER
Group type: OTHER
Intervention: Remain on wait list
Description: Remain on wait list for a more compatible organ offer if desentization with institutional protocol is not appropriate
Study: NCT04628793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07258669
Description: PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Study: NCT05878678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed positions of arm down and arm up
Description: In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed positions of arm down and arm up
Description: In order to explore the accuracy of breast cancer patients' treatment positions and its impact on dose of the new fixation device in two different fixed positions of arm up and arm down, optimize the position fixed equipment and methods of particle radiotherapy for breast cancer, and then establish the precision process of particle radiotherapy for breast cancer under the guidance of multimodal images.
Study: NCT06247241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMB-100
Description: VMB-100 is administered as intrasphincteric injection in the urethra sphincter
Study: NCT06029842

Intervention type: OTHER
Group type: OTHER
Intervention: Collaborative approach of clinical pharmacist with physicians in a medical center
Description: For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
Study: NCT05714449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye patch
Description: standard amblyopia treatment
Study: NCT05794360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACtive Children Enhance LEaRning and AttenTION (ACCELERATION)
Description: A diverse group of key informants (i.e., PE teachers, school athletic department director) and community stakeholders (i.e., professional soccer coaches, Houston Dynamo Academy director) were engaged to help the research team design, modify, and implement the ACCELERATION curriculum to ensure program relevance and appeal. There are several components that described below make our program design both comprehensive and highly adaptable for optimal reach and effectiveness. These include staff development training, parent workshops, on-site and virtual developmental programs, delivery and implementation support from community stakeholders, online resources, family engagement events, equipment donations to improve activity, and on-going support and mentoring services for parents and school-based educators.
Study: NCT04932057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation Training
Description: Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation Training
Description: Action observation training is a relatively new rehabilitation approach in which the subject is asked to carefully observe the actions presented through a video clip or performed by an operator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Action Practice
Description: Participants perform an upper extremity functionality test a couple of times.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation
Description: Participants will watch a slide show of landscape
Study: NCT05923606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Study: NCT05714449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: After-image and MIT trainer
Description: Common clinical training for foveation
Study: NCT06440122

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET Scan
Description: Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG-PET Scan
Description: Positive for activated brown adipose tissue (SUVmax \>1.5) FDG-PET scan
Study: NCT06427096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: The multifaceted interventions is comprised of the following components:~1. To establish a BP management team led by healthy family instructor. The team members also include family leaders and village doctors.~2. To conduct multifaceted intervention, which includes low-sodium diet, weight management, physical exercise, BP monitoring and antihypertensive treatment.
Study: NCT05042323

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TF-CBT-Short
Description: Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TF-CBT-Short
Description: Participants receive either 4-5 sessions of TF-CBT-Skills or TF-CBT-Narr. If the participant still has significant PTSS they are provided with step two which is the components provided in the arm they did not receive.
Study: NCT06028152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-of-life conversation game called Hello
Description: To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').~Other Name: Previously named My Gift of Grace
Study: NCT06538051

Intervention type: OTHER
Group type: OTHER
Intervention: lying positions
Description: All patients were placed in supine, semi-fowler's and lateral positions, respectively. The effects of positions on hemodynamic parameters were examined.
Study: NCT05923606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS
Description: Active tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tACS
Description: Placebo tACS will be administered over the left dorsolateral prefrontal cortex for approximately 25 minutes.
Study: NCT06397118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Nutrition Education
Description: Community Health Worker delivered Maternal Nutrition Education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care in the sickle cell disease (SCD) clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care in the sickle cell disease (SCD) clinic
Study: NCT04726449

Intervention type: OTHER
Intervention: Screening for acute confusional state
Description: The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted

Intervention type: OTHER
Intervention: Screening for acute confusional state
Description: The intervention will consist of two psychometric test to screen for acute confusional state with the usual physical examination by the emergency physician. The neurological examination abnormalities will be noted